
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ADAMTS-15 CRISPR/Cas9 KO Plasmid (h) | sc-405885 | 20 µg | $397.00 |
ADAMTS15 encodes ADAMTS-15, a secreted zinc-dependent metalloproteinase of the ADAMTS family that contributes to extracellular matrix (ECM) organization through proteolytic processing of matrix components and regulation of tissue remodeling. By shaping pericellular proteoglycan and collagen-rich microenvironments, ADAMTS-15 influences cell adhesion, migration, and mechanotransduction pathways linked to stromal–epithelial interactions. Altered ADAMTS15 activity has been studied in contexts of cartilage and connective tissue homeostasis, fibrosis-related remodeling, and tumor-associated ECM dynamics, where shifts in protease–inhibitor balance can affect invasion and metastatic potential. These features make ADAMTS-15 a useful node for investigating matrix turnover, microenvironment signaling, and protease networks in human cell systems.
ADAMTS-15 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the ADAMTS15 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the ADAMTS15 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the ADAMTS15 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish ADAMTS-15 protein expression.
This CRISPR knockout system enables efficient generation of ADAMTS15-deficient cell models for investigation of ADAMTS-15 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.